Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injectable solution for subcutaneous or intravenous administration. It is used to prevent and treat venous thromboembolic disorders, including deep vein thrombosis and pulmonary embolism, in adult patients.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides regulatory‑approved batches, ensures cold‑chain logistics where required, and supports import documentation for global distribution. Clients benefit from consistent product quality, on‑time delivery, and dedicated technical support throughout the procurement process.

Innohep (tinzaparin sodium) is employed in the management of venous thromboembolic conditions.

Prevention of deep vein thrombosis (DVT) in surgical patients: reduces postoperative clot formation and associated complications. Treatment of acute deep vein thrombosis: facilitates clot resolution and prevents propagation. Treatment and prevention of pulmonary embolism: lowers risk of embolic events and recurrence.

Tinzaparin sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection‑site pain or erythema. - Bruising or hematoma at the injection site. - Mild bleeding such as epistaxis or gum bleeding. - Transient gastrointestinal discomfort.

Serious or Rare Side Effects: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT). - Spinal or epidural hematoma, especially after neuraxial procedures. - Severe allergic reactions, including anaphylaxis.

When using Innohep, clinicians should consider several safety measures.

Renal impairment: dose adjustment may be required in severe renal dysfunction. Bleeding risk: avoid in patients with active bleeding or high bleeding propensity. Recent surgery or trauma: postpone administration until hemostasis is achieved. Concomitant anticoagulants: monitor closely when used with warfarin, DOACs, or antiplatelet agents. Pregnancy: safety not established; use only if benefit outweighs potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants). - Thrombolytic therapy (e.g., alteplase). - Neuraxial anesthesia or spinal puncture. - Non‑steroidal anti‑inflammatory drugs (NSAIDs). - Antiplatelet agents such as aspirin or clopidogrel.

Moderate Interactions (Monitor Closely): - Concurrent low‑dose heparin therapy. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs). - Corticosteroids that may increase bleeding tendency.